Pirtobrutinib
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Non-Hodgkin
Conditions
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma
Trial Timeline
Aug 7, 2025 → May 1, 2030
NCT ID
NCT07162181About Pirtobrutinib
Pirtobrutinib is a phase 2 stage product being developed by Eli Lilly for Lymphoma, Non-Hodgkin. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07162181. Target conditions include Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05172700 | Pre-clinical | Completed |
| NCT07162181 | Phase 2 | Recruiting |
| NCT06876662 | Approved | Recruiting |
| NCT06876649 | Approved | Recruiting |
| NCT06812715 | Phase 2 | Recruiting |
| NCT06588478 | Phase 2 | Recruiting |
| NCT06258174 | Phase 1 | Completed |
| NCT06190678 | Phase 1 | Completed |
| NCT06180980 | Phase 1 | Completed |
| NCT06190691 | Phase 1 | Completed |
| NCT06181006 | Phase 1 | Completed |
Competing Products
20 competing products in Lymphoma, Non-Hodgkin